Nama Insights

Alto Neuroscience (ANRO)

Healthcare · Biotechnology · NYSE

Alto Neuroscience (ANRO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.06B and a free-cash-flow yield of -6.8%. Nama's AI scorecard rates it Sell, 4.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 4.0/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Rising · +64.8% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-32.3%
How far the last close sits under the highest price of the past five years.
Market cap$1.06B
Trailing P/E—
Price / book3.6
Price / sales—
FCF yield-6.8%
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta1.4
ExchangeNYSE
SectorHealthcare
IndustryBiotechnology

ANRO earnings

Next report: Mar 15, 2027 (Q4 2026, EPS estimate -$0.66). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 10, 2026 -$0.54 -$0.72 +25.0% $0
Q2 2026 Aug 12, 2026 -$0.65 -$0.77 +15.6% $0
Q1 2026 May 13, 2026 -$0.80 -$0.50 -60.0% $0
Q4 2025 Mar 16, 2026 -$0.45 -$0.51 +11.8% $0

ANRO analyst price target

Median target $37.00 from 9 analysts, ranging $26.00 – $60.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live ANRO data on Nama Insights →

ANRO FAQ

Is ANRO a buy?
Nama's AI scorecard currently rates Alto Neuroscience Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ANRO report earnings?
Alto Neuroscience's next scheduled report is on Mar 15, 2027. Analysts expect EPS of -$0.66.
What is the ANRO price target?
The median analyst price target from 9 analysts is $37.00, with a range of $26.00 – $60.00.
Is ANRO Shariah compliant?
Nama's AAOIFI-style screen reads Alto Neuroscience as Not Shariah Compliant. At least one of the three ratios or the industry test failed.